Core Insights - Hardman Johnston Global Advisors reported underperformance in its portfolio for Q3 2025, with a return of 5.02% net of fees, compared to 7.62% for the MSCI AC World Net Index [1] Company Performance - Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is highlighted as a key stock, with a one-month return of 8.76% and a 52-week gain of 15.91% [2] - As of December 26, 2025, Vertex's stock closed at $462.90 per share, with a market capitalization of $118.683 billion [2] Challenges and Opportunities - Vertex Pharmaceuticals faced challenges in Q3 2025, with underperformance attributed to macro uncertainties from a Section 232 tariff investigation into medical devices and setbacks in chronic pain treatment developments [3] - The company ended its pursuit of a broad chronic neuropathic pain label for Journavx, which limited its total addressable market (TAM) in chronic pain, despite the drug being approved for acute pain with positive initial indications [3] - Vertex's next-generation pain asset, VX-993, failed in phase II development, impacting stock performance [3] - Positive updates were noted in other areas, including progress in treatments for kidney disease, type 1 diabetes, and gene-editing therapy, indicating a strong pipeline [3] - The launch of Alyftrek, a next-generation cystic fibrosis treatment, is underway, with patients transitioning from Trikafta, which is expected to improve margins due to a lower royalty burden [3] - The long-term outlook for Vertex remains positive, supported by its high-margin cystic fibrosis franchise and a robust balance sheet [3]

Core Insights - The roundtable discussion hosted by Lexicon Pharmaceuticals focused on enhancing legislative efforts to address chronic pain treatment needs in the U.S. [1][3] - Approximately 50 million Americans suffer from chronic pain, with associated costs reaching up to $635 billion annually [2] - The Alternatives to PAIN Act aims to improve access to non-opioid pain treatments under Medicare Part D, currently limited to acute and post-surgical pain [3][4] Legislative Focus - Participants discussed the need to expand the Alternatives to PAIN Act to include chronic pain sufferers [3] - The group emphasized the importance of innovation in pain treatment, highlighting that pain remains an undertreated condition [4] Company Overview - Lexicon Pharmaceuticals is dedicated to pioneering medicines that transform patients' lives, utilizing its Genome5000™ program for drug discovery [5] - The company has a pipeline of drug candidates targeting various conditions, including neuropathic pain and obesity [5]